

BEST AVAILABLE COPY

In the Claims:

1. (Currently amended) A pharmaceutical composition for reducing angiogenesis in tumor cells, the method comprising

monoclonal anti-CD66a ~~4D1/C2~~ antibody which was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998 and a pharmaceutically compatible carrier, wherein the monoclonal anti-CD66a ~~4D1/C2~~ antibody is in a therapeutically active amount to reduce formation of capillaries in the tumor cells by functionally blocking CD66a on tumor endothelial cell.

2. (Currently amended) The composition according to claim 1, characterized in that the monoclonal anti-CD66a ~~4D1/C2~~ antibody which functionally blocks CD66a binds specifically to one or more functional domains of CD66a.

3. (Cancelled)

4. (Cancelled)

5. (Withdrawn) The composition according to claim 1(b), characterized in that the substances which inhibit the expression of CD66a or CD66a ligand are anti-sense oligonucleotides or anti-sense RNA.

6. (Previously presented) The composition according to claim 1, characterized in that it is capable of reducing tumor angiogenesis of lung cancer, breast cancer and colon carcinoma.

7. (Withdrawn) The composition according to claim 1, characterized in that the substances inducing the expression of CD66a or CD66a ligand are DNA coding for CD66a, Cd66a isoforms or CD66a fragments.

8. (Currently amended) A pharmaceutical composition for inhibiting *in vitro* angiogenesis in tumor cells, comprising a monoclonal anti-CD66a ~~4D1/C2~~ antibody which was deposited with DSMZ

BEST AVAILABLE COPY

(German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998 and a pharmaceutically compatible carrier, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in an effective amount to reduce formation of capillaries in tumor cell cultures by functionally blocking CD66a receptor on tumor endothelial cells.

9. (Withdrawn) A method for reducing angiogenesis in tumor cells, the method comprising; administering a monoclonal anti-CD66a 4D1/C2 antibody in a pharmaceutically compatible carrier, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in a therapeutically active amount to reduce formation of capillaries in the tumor cells by functionally blocking CD66a on tumor endothelial cell and wherein the antibody was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998.

10. (Withdrawn) An *in vitro* method for reducing angiogenesis in tumor cells, the method comprising; administering a monoclonal anti-CD66a 4D1/C2 antibody in a pharmaceutically compatible carrier to tumor endothelial cells, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in a therapeutically active amount to reduce formation of capillaries in the tumor cells by functionally blocking CD66a on tumor endothelial cell and wherein the antibody was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998.